

Lentiviral short hairpin RNA screen of human kinases and phosphatases to identify potential biomarkers in oral squamous cancer cells

Ming-Han Yeh¹, Tzung-Chieh Tsai³, Han-Peng Kuo¹, Nai-Wen Chang^{4,#}, Miao-Rong Lee⁴,
Jing-Gung Chung⁵, Ming-Hsui Tsai⁶, Jah-Yao Liu^{1,7,*} and Ming-Ching Kao^{1,2,5,*}

¹ Graduate Institute of Life Sciences, National Defense Medical Center, No.161, Section 6, Min-Chuan East Road, Taipei 11490, Taiwan, ROC.

² Department of Biochemistry, National Defense Medical Center, No.161, Section 6, Min-Chuan East Road, Taipei 11490, Taiwan, ROC.

³ Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, No.300, Syuefu Road, Chiayi 60004, Taiwan, ROC.

⁴ Department of Biochemistry, College of Medicine, China Medical University, No.91, Hsueh-Shih Road, Taichung, Taiwan 40402, ROC.

⁵ Department of Biological Science and Technology, College of Life Sciences, China Medical University, No.91, Hsueh-Shih Road, Taichung, Taiwan 40402, ROC.

⁶ Department of Otolaryngology, China Medical University Hospital, China Medical University Hospital, No.2, Yuh-Der Road, Taichung, Taiwan 40447, ROC.

⁷ Department of Obstetrics and Gynecology, Tri-Service General Hospital, No.325, Section 2, Chenggong Road, Taipei, Taiwan 11490, ROC.

***Requests for reprints:** Ming-Ching Kao, Department of Biological Science and Technology, College of Life Sciences, China Medical University, 91 Hsueh-Shih Road, Taichung, Taiwan 40402, ROC. Tel: +886-4-22053366 ext. 2206; Fax: +886-4-22071507; Email: mckao@mail.cmu.edu.tw; or Jah-Yao Liu, Department of Obstetrics & Gynecology,

Tri-Service General Hospital, No.325, Section 2, Chenggong Road, Taipei, Taiwan 11490, ROC. Tel: +886-2-87923311 ext. 12828; Fax: +886-2-27931272; Email: jyliu@mail.ndmctsgh.edu.tw.

Running title: shRNA screening for oral cancer biomarkers

Key words: Oral Cancer; RNA Interference; High-Throughput Screening Assays; Kinases; Phosphoprotein Phosphatases; Biomarkers

Abstract

Oral carcinoma is a serious public health problem and the leading cause of head and neck cancer mortality worldwide. Moreover, oral cancer patients often present symptoms at a late stage and show a high recurrence rate after treatment. Therefore, there is an urgent need to identify novel biomarkers for early diagnosis or clinical oral cancer therapy. In this study, we employed subset of lentiviral short hairpin RNAs targeted against various kinases and phosphatases, designed by The RNAi Consortium, to screen systemically and in a high-throughput manner for potential growth regulators of oral cancer cells. The screen revealed a total of 50 candidate genes, for which more than 90% of growth inhibition in human oral squamous cancer HSC-3 cells was obtained. Furthermore, a bioinformatics analysis of these candidate genes identified transforming growth factor- β receptor type II- and fms-related tyrosine kinase 3-related molecular pathways that involve in NF- κ B-mediated growth of HSC-3 cells. These candidate genes may be potential biomarkers for early diagnosis of oral cancer. In addition, these candidate genes represent potential targets for anti-cancer drug design helping to develop a personalized treatment to combat with oral cancer.

Introduction

Head and neck cancer is the sixth most common type of cancer in the world. It arises from epithelial malignancies originating in paranasal sinuses, nasal cavity, oral cavity, pharynx, and larynx (1). Among these malignancies, oral squamous cell carcinoma (OSCC) is the most prevalent diagnosed malignancy and the leading cause of head and neck cancer death worldwide (2). Several risk factors for OSCC, including smoking, alcohol drinking, betel quid consumption, human papillomavirus infection, and genetic factors have been reported and well studied for many years (3-8). The early clinical diagnosis of OSCC is mainly based on screening for leukoplakia on oral cavity examination. If a precancerous lesion is present, it will subsequently be histologically classified as slight, moderate, or severe hyperplasia, or carcinoma *in situ*. A higher degree of dysplasia often correlates with a higher possibility that a lesion transforms into a malignant tumor (9). However, a number of studies suggest that this prediction criterion is not reliable enough; in particular, early genetic changes may not necessarily result in observable changes in morphology (10-12). Therefore, identifying novel biomarkers for early diagnosis of OSCC may open up novel therapeutic strategies and/or improve the efficacy of therapeutic treatment.

It is well known that genetic alterations are the defining features of cancer and disturb the signal transduction network in cancer cells, resulting in inappropriate cellular growth, survival and death (13). Protein kinases and phosphatases are important regulators of cell signaling pathways by governing reversible phosphorylation. Deregulation of kinase or phosphatase activities by genetic alterations causes malignant transformation. Hence, identification of novel kinases and phosphatases responsible for those aberrant cell behaviors will significantly advance our understanding of human oral oncogenesis, subsequently leading to more effective treatments and novel therapeutic strategies (14, 15). For example, *epidermal growth factor receptor (EGFR)* has been identified to be amplified in 31% of OSCC patients and correlates

with poor clinical outcome. Targeting of EGFR with either a monoclonal antibody against EGFR or a small-molecule EGFR tyrosine kinase inhibitor has been successfully utilized for therapeutic purposes (16, 17).

Currently, it is believed that personalized treatment is the major cancer therapy strategy in the future. Thus, identification of biomarkers of OSCC, such as kinases and phosphatases, is required to achieve this goal (18). To identify kinases and phosphatases for early diagnosis or as therapeutic targets for OSCC, we employed “anti-kinome” and “anti-phosphatome” lentiviral short hairpin RNA (shRNA) subset to perform high-throughput screening for growth regulators of human OSCC cell line HSC-3. Furthermore, the possible cellular pathways for these OSCC-related regulators were also investigated.

Materials and Methods

Cell culture

Human OSCC cell line HSC-3 was obtained from the Japanese Collection of Research Bioresources. HSC-3 cells were cultured in DMEM/F12 medium (Gibco) supplemented with 10% FBS (Hyclone) and maintained at 37°C in a humidified atmosphere with 5% CO₂.

Lentivirus-based shRNA high-throughput screening

The VSV-G pseudotyped lentivirus-based human kinase and phosphatase subset (KP subset) was obtained from the National RNAi Core Facility (NRCF) located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica (Taipei, Taiwan, ROC), supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 97-3112-B-001-016). The lentivirus-based shRNA system from NRCF was adopted from The RNAi Consortium (TRC) (19). TRC designed multiple distinct shRNA clones to target each gene, and shRNA oligonucleotides were constructed into lentiviral vector pLKO.1-puro to

produce VSV-G pseudotyped lentivirus. The KP subset covered 1236 genes in total, including 737 kinases, 209 phosphatases and 30 genes with dual function. Conversion of relative infection unit (R.I.U) for HSC-3 cells and lentivirus-based shRNA high-throughput screen were adopted by following the protocol of TRC. In brief, for a single shRNA clone, HSC-3 cells were seeded in DMEM/F12 medium in the day before lentivirus transfection at 3×10^3 cells per well in 96-well plates. After 24 h, medium was removed and replaced with fresh DMEM/F12 medium supplemented with 10 $\mu\text{g/ml}$ polybrene, and then lentivirus was added to cells (MOI=3). Medium was removed 24 h post-infection and cells were washed with DPBS. Subsequently, fresh HSC-3 cells growth medium supplemented with 5 $\mu\text{g/ml}$ puromycin was added. After 48 h, medium was removed and replaced with fresh HSC-3 cells growth medium and Cell Counting Kit-8 solution (CCK-8, Dojindo). The plate was incubated for 3 h and then the absorbance at 450 nm was measured. Each shRNA clone infection was performed in duplicate, in two independent 96-well plates. Absorbance values were normalized for each shRNA clone and the average of the duplicates determined to obtain the average percentage of growth inhibition relative to the control.

Bioinformatics analysis

Candidate genes were analyzed using MetaCoreTM (GeneGo) as described (20).

shRNA transfection

Liposome-mediated transfection of shRNA was performed as described (21). Briefly, cells were seeded the day before shRNA transfection. On the day of transfection, plasmids containing shRNA cassettes and Lipofectamine 2000 (Invitrogen) were separately diluted into Opti-MEM medium (Invitrogen), mixed and incubated for 20 min at room temperature. The resulting lipoplex complex was then added to the cells. After incubation for 6 h, lipoplexes

were removed and replaced with fresh DMEM/F12 medium. Cells were harvested for further assays at the indicated time point.

Viability assay

Cell viability assay was performed using 96-well dish and CCK-8 reagent (Dojindo). Cells were incubated with CCK-8 solution at 37°C for 3 h after transfection with shRNA or treatment with specific tyrosine kinase inhibitor LY-364947 (Sigma-Aldrich) or Sunitinib malate (BioVision), respectively. Then the absorbance of each well was measured at 450 nm by ELISA reader.

Real-time PCR

Total RNA was isolated 48 h after transfection from HSC-3 cells by using Trizol reagent (Invitrogen) and converted into cDNA by using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time PCR reactions were performed by using Power SYBR Green Master Mix (Applied Biosystems). Sequences of FLT3 primers (sense: 5'-TCAAGTGCTGTGCATACAATTCCC-3', antisense: 5'-CACCTGTACCATCTGTAGCTGGCT-3') are as previously described (22). Primers of TGFBR2 (sense: 5'-GGGGAAACAATACTGGCTGA-3', antisense: 5'-GAGCTCTTGAGGTCCTGTG-3'), IKBKB (sense: 5'-GCTGCAACTGATGCTGATGT-3', antisense: 5'-TGTCACAGGGTAGGTGTGGA-3'), SHC1 (sense: 5'-GCCGAGTATGTCGCCTATGT-3', antisense: 5'-GGGTGGGTT-CCTGAGGTATT-3'), SMAD4 (sense: 5'-CCATTTCCAATCATCCTGCT-3', antisense: 5'-ACCTTTGCCTATGTGCAACC-3') and the internal control GAPDH gene (sense: 5'-AATGGAAATCCCATCACCATCTT-3', antisense: 5'-CATCGCCCCACTTGATTTTG-3') were designed using the Primer Express™

software (Applied Biosystems) to specifically amplify the indicated genes. Amplification reactions and data analysis were performed according to the manufacturer's instructions in an ABI PRISM 7900 instrument (Applied Biosystems). The comparative CT method was used for relative quantification of gene expression.

Western blot analysis

Western blot analysis was conducted as previously described (23). Monoclonal antibodies against TGFBR2, FLT3, IKBKB, SHC1, phospho-SHC1 (Y317) and SMAD4 were purchased from Abcam, while anti-phospho-*IKBKB* (S177) was purchased from Cell Signaling Technology. The anti- β -actin monoclonal antibody was purchased from Chemicon. The secondary antibodies horseradish peroxidase (HRP)-linked goat anti-mouse IgG and HRP-linked goat anti-rabbit IgG were purchased from Santa Cruz Biotechnology and Cell Signaling Technology, respectively.

Immunofluorescence Microscopy

To investigate the subcellular localization of Nuclear Factor- κ B (NF- κ B), HSC-3 cells were fixed and permeabilized according to the manufacturer's instructions (Invitrogen). Briefly, HSC-3 cells were transfected with indicated shRNA for 48 h, fixed by incubation for 20 min at room temperature in DPBS containing 4% formaldehyde, and then permeabilized by incubation for 20 min on ice in DPBS containing 0.2% Triton X-100. Fixed cells were blocked with 5% bovine serum albumin (Sigma-Aldrich) and incubated with anti-NF- κ B monoclonal antibodies (Santa Cruz) for 1 h, followed by incubation with goat-anti-rabbit Alexa fluor® 488 secondary antibody (Invitrogen) for 1 h with washing in between. Finally, cells were stained with Hoechst 33328 (Sigma-Aldrich) for 10 min at room temperature. Subcellular localization of NF- κ B was observed by using a Leica TCS SP2 confocal

microscope (Leica Microsystems).

Biohazard

All experiments involving lentivirus-based shRNA were performed in a P2 Lab under the Institutional Biosafety Guideline.

Statistical analysis

The quality of screening results were determined by using the Z factor (24). The criteria of potential candidate genes used a Z factor cutoff of above 0. All data were analyzed by using the paired Student's t-test for comparison of independent means. $P < 0.05$ (two-tailed) was considered to be significant.

Results

Lentivirus-based shRNA high-throughput screen to identify genes required for growth of oral cancer cells

To identify genes involved in growth regulation of human oral cancer cells, we screened human OSCC cell line HSC-3 by using a lentivirus-based shRNA subset against human kinases and phosphatases. NRCF determined the relative viral titer with regard to the A549 cell line. Because different cell lines might respond differently to VSV-G pseudotyped lentivirus, we converted the R.I.U from A549 to HSC-3 cells. To this end, we generated a line chart of HSC-3 cell viability versus a serially diluted titer of control shLuc virus and then established a standard curve for lentivirus transfection titer. Next, we converted the R.I.U for HSC-3 cells and determined the virus titer and MOI according to the standard curve. Then, based on the converted R.I.U, we adopted the lentivirus-based shRNA high-throughput screening and analyzed the viability of HSC-3 cells after virus infection for 72 h. The

preliminary screening results, as shown in Fig. 1, yielded 50 genes (equivalent to 116 shRNA clones), which were then selected as candidates for further evaluation (about 4% hit rate). To recognize potential off-target effects of shRNA, two or more shRNAs for each gene were used. Only genes, for which growth of HSC-3 cells was significantly inhibited (> 90%) by at least two shRNA clones with a Z factor above 0, were selected as candidates. The information of these candidate shRNA clones are listed in Table 1. Then, bioinformatics analysis was conducted to study the relationship between these candidate genes.

Bioinformatics analysis reveals potential biomarkers and molecular pathways that are involved in growth of oral cancer

To further determine the molecular signaling pathways regulating the growth of HSC-3 cells, all candidate genes were subjected to GeneGo MetaCore™ analysis. Fig. 2A shows the results from Dijkstra's shortest paths algorithm to obtain the closely related signaling molecules (25). Based on the results of MetaCore™ analysis, we propose that TGFBR2 and FLT3 regulate the growth of HSC-3 cells through activating SHC1 and IKBKB via phosphorylation followed by activation of their downstream signaling pathways, resulting in NF-κB translocation from cytoplasm to nucleus then transcribing genes that promote growth of HSC-3 cells. According to our results and several other reports (26-28), a putative molecular pathway is proposed in Fig. 2B.

Validation of the candidate genes

We then performed the validation for the specificity of candidate shRNAs and the correlations between shRNA-mediated gene knockdown and phenotype of cell growth inhibition. According to the results of the bioinformatics analysis, the major components (i.e., TGFBR2, FLT3, SHC1 and IKBKB) of this putative molecular signaling pathway and some

relevant candidate genes (i.e., CBLB, CDKN1A, MAPK14 and SMAD4) were chosen for validation by applying a transient transfection system to deliver their corresponding shRNAs into HSC-3 cells. First, we examined whether the expression of candidate genes were knocked down by their specific shRNAs. As shown in Fig. 3A and 3B, all candidate shRNAs were able to suppress both the expression of mRNA and protein of their target genes in HSC-3 cells after 48 h transfection. Furthermore, based on the results shown in Fig. 3C, we found these candidate shRNAs could also suppress the growth of HSC-3 cells. These results demonstrated the specificity of candidate shRNAs.

Suppression of TGFBR2 and FLT3 downregulates SHC1 and IKBKB resulting in NF- κ B translocation and growth inhibition of HSC-3 cells

To unravel the putative molecular signaling pathway predicted by bioinformatics analysis, HSC-3 cells were transfected with either TGFBR2 shRNAs (#832, #833) or FLT3 shRNAs (#9886, #9888), respectively, and protein expression and phosphorylation level of SHC1 and IKBKB were measured by western blot analysis (Fig. 4A). Both protein expression and phosphorylation level of SHC1 and IKBKB were decreased by TGFBR2 or FLT3 shRNAs. Furthermore, subcellular localization of NF- κ B was also changed from cytoplasm to nucleus after transfection with either TGFBR2 shRNAs (#832, #833) or FLT3 shRNAs (#9886, #9888) for 48 h (Fig. 4B). In addition, growth inhibition of HSC-3 cells were also observed by using tyrosine kinase antagonists LY-364947 and Sunitinib malate against TGFBR2 and FLT3, respectively. Taken together, these results revealed a putative molecular signaling pathway which regulates the growth of HSC-3 cells.

Discussion

With the advancement of genomics technologies, now scientists can easily study various kinds of human disease followed by their molecular signature (29). Among these tools, RNAi provides a comprehensive approach to specifically knock down gene function in a high-throughput fashion in mammalian cells (30). In this study, we used the KP subset to identify potential growth regulators of HSC-3 cells. The screening results identified 50 candidate genes that may be involved in the growth regulation of HSC-3 cells. Inhibition of these candidate genes resulted in significant growth inhibition effect on HSC-3 cells, showing these candidate genes, like oncogenes, may play a role in “promoting” the growth of OSCC cells. On the other hand, we also identified another group of shRNAs with growth promotion effect on HSC-3 cells (data not shown). These genes, like tumor suppressor genes, may play a role in “suppressing” the growth of OSCC cells. In order to understand the molecular mechanisms regulating the growth of OSCC cells, both growth promoting and inhibiting groups of genes may be combined for further analyzing how they interact each other to regulate the growth of OSCC cells.

The 50 candidate genes were further analyzed by the bioinformatics software and revealed a putative molecular signaling pathway regulating the growth of HSC-3 cells. We found that suppression of TGFBR2 or FLT3 expression by specific shRNAs could cause downregulation of protein expression and phosphorylation of SHC1 and IKBKB. Furthermore, suppression of TGFBR2 or FLT3 led to relocalization of transcription factor NF- κ B from the cytoplasm to the nucleus. The human *FLT3* gene encodes a membrane-bound receptor tyrosine kinase (RTK), which belongs to the RTK subclass III family. FLT3 is known to play a crucial role in both normal haematopoiesis and acute myeloid leukaemia (31). Our results suggest that FLT3 may also be involved in the growth regulation of OSCC cells through regulating IKBKB and NF- κ B. To the best of our knowledge, this is the first report showing that FLT3 plays an important role in the growth regulation of OSCC cells. However, the molecular mechanisms

how FLT3 regulates IKBKB and NF- κ B remain to be further investigated. Nevertheless, small molecule drugs specifically targeting the RTK subclass III family such as FLT3, like Sunitinib, may hold potential for treating OSCC in the future (32).

The human *TGFBR2* gene belongs to the TGF- β superfamily receptors. The role of TGF- β superfamily members (TGF- β s) in carcinogenesis is similar to a double-edged sword. In normal tissues, TGF- β s act as tumor suppressors through SMAD-dependent signaling pathways. However, during carcinogenesis, TGF- β s perform oncogenic activities, either through SMAD-independent, or cooperation between alternative pathways (e.g. aberrant activation of Ras/MAPK signaling pathways) and relatively low activated SMAD pathways (33, 34). Our results show that suppression of *TGFBR2* causes growth inhibition of OSCC cells and decreases the protein expression and phosphorylation levels of SHC1 and IKBKB. Furthermore, suppression of *TGFBR2* does lead to translocalization of NF- κ B without affecting the subcellular localization of SMAD4 (Data not shown). Based on these results, it is reasonable to propose that *TGFBR2* may promote the growth of OSCC cells through regulating transcription factor NF- κ B.

Among these 50 candidate genes, several genes have been reported to be involved in regulation of apoptosis and chemoresistance in HeLa cervical carcinoma cells (35). These genes are MAP2K1IP1, PPEF2, PTEN and *TGFBR2*, which were considered as survival genes. Suppression of expression of these genes induced apoptosis or decreased chemoresistance of cancer cells against anticancer drugs like Taxol. However, our results demonstrate that growth inhibition effect caused by suppression of these genes does not induce apoptosis of HSC-3 cells (data not shown). Despite similar effects of these genes on HeLa and HSC-3 cells are not observed; both studies demonstrate that all these genes may still be important biomarkers of cancer cells.

Although PTEN and CDKN1A are known as tumor suppressors, they were also reported to play a role as positive regulators of cell growth (35). Interestingly, in our study we found that suppression of PTEN or CDKN1A resulted in growth inhibition of HSC-3 cells. It is possible that PTEN and CDKN1A may be responsible for other functions in growth regulation of tumor cells. For example, Akt-induced phosphorylation of CDKN1A increases the cytoplasmic localization and protein stability of CDKN1A, resulting in promotion of growth and survival of tumor cells (36, 37). The molecular mechanism of PTEN and CDKN1A in growth regulation of OSCC cells remains to be clarified.

The current strategy to cancer therapy is often referred to as “one drug for all”. This leads frequently to inappropriate therapy and causes patients to suffer from side effects of drug toxicity. It is believed that personalized medicine has the potential to improve this problem (18, 38). In this research, we applied the “anti-kinome” and “anti-phosphatome” lentiviral shRNA subset to high-throughput screen and identify the potential biomarkers of OSCC cells. These potential biomarkers and their putative molecular pathways may be used as targets for early diagnosis of the OSCC. Moreover, they may also be beneficial to develop personalized medicine against OSCC.

Acknowledgements

We acknowledge all lab colleagues and undergraduate students for their efforts and technical assistances on this project. We thank Dr. Ru-Chien Cheng (Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan, ROC) for providing the P2 Lab. We also thank members of the Medical Research Core Facilities Center (Office of Research & Development, China Medical University, Taichung, Taiwan, ROC) for technical assistance. This work was supported by the China Medical University project CMU95-122 and CMU97-090 granted to MCK*, and partly by the Department of Health (DOH-99-TD-C-111-005), Republic of China, granted to NWC#.

Conflict of interest statement

None declared.

References

1. Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. *Lancet* 371: 1695-1709, 2008.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. *CA Cancer J Clin* 55: 74-108, 2005.
3. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. *Oncogene* 21: 7435-7451, 2002.
4. Ogden GR: Alcohol and oral cancer. *Alcohol* 35: 169-173, 2005.
5. Chen YJ, Chang JT, Liao CT, *et al*: Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. *Cancer Sci* 99: 1507-1514, 2008.
6. Licitra L, Perrone F, Bossi P, *et al*: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. *J Clin Oncol* 24: 5630-5636, 2006.
7. Chang NW, Pei RJ, Tseng HC, *et al*: Co-treating with arecoline and 4-nitroquinoline 1-oxide to establish a mouse model mimicking oral tumorigenesis. *Chem Biol Interact* 183: 231-237, 2010.
8. Califano J, van der Riet P, Westra W, *et al*: Genetic progression model for head and neck cancer: implications for field cancerization. *Cancer Res* 56: 2488-2492, 1996.

9. Campo-Trapero J, Cano-Sanchez J, Palacios-Sanchez B, Sanchez-Gutierrez JJ, Gonzalez-Moles MA and Bascones-Martinez A: Update on molecular pathology in oral cancer and precancer. *Anticancer Res* 28: 1197-1205, 2008.
10. Kujan O, Oliver RJ, Khattab A, Roberts SA, Thakker N and Sloan P: Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. *Oral Oncol* 42: 987-993, 2006.
11. Rosin MP, Cheng X, Poh C, *et al*: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. *Clin Cancer Res* 6: 357-362, 2000.
12. Partridge M, Pateromichelakis S, Phillips E, Emilion GG, A'Hern RP and Langdon JD: A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. *Cancer Res* 60: 3893-3898, 2000.
13. Hanahan D and Weinberg RA: The hallmarks of cancer. *Cell* 100: 57-70, 2000.
14. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. *Nature* 411: 355-365, 2001.
15. Ostman A, Hellberg C and Bohmer FD: Protein-tyrosine phosphatases and cancer. *Nat Rev Cancer* 6: 307-320, 2006.
16. Sheu JJ, Hua CH, Wan L, *et al*: Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. *Cancer Res* 69: 2568-2576, 2009.
17. Hamakawa H, Nakashiro K, Sumida T, *et al*: Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. *Head Neck* 30: 800-809, 2008.
18. Duffy MJ and Crown J: A personalized approach to cancer treatment: how biomarkers can help. *Clin Chem* 54: 1770-1779, 2008.
19. Moffat J, Grueneberg DA, Yang X, *et al*: A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. *Cell* 124: 1283-1298, 2006.

20. Ekins S, Nikolsky Y, Bugrim A, Kirillov E and Nikolskaya T: Pathway mapping tools for analysis of high content data. *Methods Mol Biol* 356: 319-350, 2007.
21. Ou CC, Hsu SC, Hsieh YH, *et al*: Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. *Carcinogenesis* 29: 299-306, 2008.
22. Rosnet O, Schiff C, Pebusque MJ, *et al*: Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. *Blood* 82: 1110-1119, 1993.
23. Chuang TC, Liu JY, Lin CT, *et al*: Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy. *FEBS Lett* 581: 4443-4449, 2007.
24. Birmingham A, Selfors LM, Forster T, *et al*: Statistical methods for analysis of high-throughput RNA interference screens. *Nat Methods* 6: 569-575, 2009.
25. Dijkstra EW: A note on two problems in connexion with graphs. *Numerische Mathematik* 1: 269-271, 1959.
26. Neil JR and Schiemann WP: Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. *Cancer Res* 68: 1462-1470, 2008.
27. Grosjean-Raillard J, Ades L, Boehrer S, *et al*: Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. *Apoptosis* 13: 1148-1161, 2008.
28. Ondrey FG, Dong G, Sunwoo J, *et al*: Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. *Mol Carcinog* 26: 119-129, 1999.
29. Chen X, Jorgenson E and Cheung ST: New tools for functional genomic analysis. *Drug Discov Today* 14: 754-760, 2009.

30. Moffat J and Sabatini DM: Building mammalian signalling pathways with RNAi screens. *Nat Rev Mol Cell Biol* 7: 177-187, 2006.
31. Stirewalt DL and Radich JP: The role of FLT3 in haematopoietic malignancies. *Nat Rev Cancer* 3: 650-665, 2003.
32. Chow LQ and Eckhardt SG: Sunitinib: from rational design to clinical efficacy. *J Clin Oncol* 25: 884-896, 2007.
33. Lu SL, Reh D, Li AG, *et al*: Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. *Cancer Res* 64: 4405-4410, 2004.
34. Wakefield LM and Roberts AB: TGF-beta signaling: positive and negative effects on tumorigenesis. *Curr Opin Genet Dev* 12: 22-29, 2002.
35. MacKeigan JP, Murphy LO and Blenis J: Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. *Nat Cell Biol* 7: 591-600, 2005.
36. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. *Nat Cell Biol* 3: 245-252, 2001.
37. Li Y, Dowbenko D and Lasky LA: AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. *J Biol Chem* 277: 11352-11361, 2002.
38. Allison M: Is personalized medicine finally arriving? *Nat Biotechnol* 26: 509-517, 2008.

Figure legends

Figure 1. Putative genes with growth inhibition as identified through lentivirus-based shRNA high-throughput screening. In total, 50 genes (equivalent to 116 shRNA clones) were selected as candidates. Each gene had more than two shRNA clones with growth inhibition effect of more than 90% of HSC-3 cells when compared with negative control shLuc. Each bar represents the mean of growth inhibition effect of each shRNA clone on HSC-3 cells

Figure 2. Bioinformatics analysis reveals novel biomarkers and molecular pathways involved in oral cancer HSC-3 cell. **A**, Based on the lentivirus-based shRNA high-throughput screening results followed by bioinformatics analysis, candidate biomarkers and their possible molecular pathways were identified. **B**, Novel biomarkers and putative molecular signaling pathways involved in the growth regulation of oral cancer HSC-3 cells.

Figure 3. Validation of the candidate shRNAs with target inhibition effect in HSC-3 cell. Candidate shRNAs were transfected into human oral cancer HSC-3 cells by using liposome as transfection reagent. **A**, HSC-3 cells were harvested 48 h after transfection, followed by total RNA isolation and conversion into cDNA. Subsequently, the gene expression level was measured by real-time PCR and normalized against negative control shLuc. **B**, (*Upper panel*) HSC-3 cells were harvested after transfection with TGFBR2 shRNAs (#832, #833) or FLT3 shRNAs (#9886, #9888) for 24 h, 48 h and 72 h. (*Lower panel*) HSC-3 cells were harvested after transfection with shRNAs of SHC1, IKBKB and SMAD4 for 48 h, respectively, and protein expression level was analyzed by western blotting **C**, Growth inhibition of HSC-3 cells relative to control shLuc was measured by CCK-8 48 h after transfection. $P < 0.05$, control versus all candidate shRNAs. Data are mean \pm SD of at least three independent experiments.

Figure 4. Suppression of FLT3 and TGFBR2 downregulates SHC1 and IKBKB. **A**, HSC-3 oral cancer cells were transfected with FLT3 shRNAs (#9886, #9888) or TGFBR2 shRNAs (#832, #833), separately. Protein expression and phosphorylation level of SHC1 and IKBKB were measured by western blot analysis. **B**, HSC-3 cells were fixed after transfection with either TGFBR2 shRNAs (#832, #833) or FLT3 shRNAs (#9886, #9888) and incubation for 48 h, and the subcellular localization of NF- κ B was detected by confocal microscopy. **C**, HSC-3 cells were treated with tyrosine kinase antagonist LY-364947 (50, 100, 200, and 400 μ M) or Sunitinib malate (5, 10, 20, and 40 μ M) for 24 h, 48 h and 72 h, respectively. Cell viability was measured by CCK-8. Results are represented as mean \pm SD of at least three independent experiments. *, $P < 0.05$. **, $P < 0.01$. All assays were performed at least three times.

Table 1. List of candidate shRNA clones with growth inhibition effects on HSC-3 cells.

NCBI nucleotide accession number	Gene Name	TRC Clone number	Growth inhibition (%)	Z score
NM_000059	breast cancer 2, early onset (BRCA2)	TRCN0000040196	99.53	0.15
		TRCN0000040197	95.63	0.09
NM_007371	bromodomain containing 3 (BRD3)	TRCN0000021374	99.84	0.47
		TRCN0000021375	97.64	0.46
NM_001744	calcium/calmodulin-dependent protein kinase IV (CAMK4)	TRCN0000000580	98.17	0.33
		TRCN0000009960	98.70	0.47
NM_170662	Cas-Br-M (murine) ecotropic retroviral transforming sequence b (CBLB)	TRCN0000007751	94.54	0.39
		TRCN0000007752	99.32	0.47
NM_000389	cyclin-dependent kinase inhibitor 1A (CDKN1A, p21, Cip1)	TRCN0000040124	97.87	0.14
		TRCN0000040125	99.65	0.09
NM_005192	cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase) (CDKN3)	TRCN0000002523	95.34	0.49
		TRCN0000002524	95.42	0.49
		TRCN0000002526	95.42	0.50
NM_001356	DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked (DDX3X)	TRCN0000000001	100.00	0.65
		TRCN0000000002	99.78	0.67
		TRCN0000000004	99.63	0.68
		TRCN0000000005	98.95	0.66
NM_152511	dual specificity phosphatase 18 (DUSP18)	TRCN0000002720	97.87	0.77
		TRCN0000002723	93.27	0.73
NM_005232	EPH receptor A1 (EPHA1)	TRCN0000006398	98.88	0.02
		TRCN0000006400	99.71	0.05
NM_178494	hypothetical protein FLJ40125 (FLJ40125)	TRCN0000002738	95.36	0.79
		TRCN0000002740	96.45	0.79
NM_004119	fms-related tyrosine kinase 3 (FLT3)	TRCN0000009886	98.33	0.46
		TRCN0000009888	96.87	0.42
NM_145059	Fucokinase (FUK)	TRCN0000037857	96.81	0.53
		TRCN0000037858	90.88	0.39
NM_152696	homeodomain interacting protein kinase 1 (HIPK1)	TRCN0000007161	98.15	0.46
		TRCN0000007163	91.76	0.30
NM_016291	inositol hexaphosphate kinase 2 (IHPK2)	TRCN0000006141	98.96	0.47
		TRCN0000006142	99.97	0.47
NM_001556	inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (IKBKB)	TRCN0000018917	99.84	0.47
		TRCN0000018918	99.95	0.46

		TRCN0000018919	96.99	0.44
NM_002221	inositol 1,4,5-trisphosphate 3-kinase B (ITPKB)	TRCN0000037711	98.54	0.65
		TRCN0000037712	97.26	0.60
NM_033360	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)	TRCN0000033261	96.12	0.63
		TRCN0000033262	99.40	0.63
NM_003682	MAP-kinase activating death domain (MADD)	TRCN0000037881	99.78	0.56
		TRCN0000037883	99.60	0.56
NM_021970	mitogen-activated protein kinase kinase 1 interacting protein 1 (MAP2K1IP1)	TRCN0000037884	99.62	0.55
		TRCN0000037887	96.66	0.52
NM_004721	mitogen-activated protein kinase kinase kinase 13 (MAP3K13)	TRCN0000007103	96.64	0.69
		TRCN0000007105	99.43	0.71
NM_139012	mitogen-activated protein kinase 14 (MAPK14)	TRCN0000010051	99.52	0.39
		TRCN0000010052	100.00	0.44
NM_002752	mitogen-activated protein kinase 9 (MAPK9)	TRCN0000001012	96.65	0.16
		TRCN0000001015	90.33	0.12
NM_031417	MAP/microtubule affinity-regulating kinase 4 (MARK4)	TRCN0000007156	99.18	0.46
		TRCN0000007157	95.78	0.38
NM_018349	multiple C2 domains, transmembrane 2 (MCTP2)	TRCN0000007117	99.76	0.47
		TRCN0000007119	97.86	0.45
		TRCN0000007120	99.76	0.47
		TRCN0000007121	99.29	0.47
NM_033115	hypothetical protein MGC16169 (MGC16169)	TRCN0000007078	99.13	0.71
		TRCN0000007079	95.74	0.65
		TRCN0000007081	97.53	0.71
NM_001932	membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3) (MPP3)	TRCN0000006133	98.85	0.49
		TRCN0000006134	100.00	0.50
NM_004145	myosin IXB (MYO9B)	TRCN0000007137	98.23	0.46
		TRCN0000007138	93.40	0.43
		TRCN0000007139	94.21	0.43
		TRCN0000007141	99.69	0.47
NM_000907	natriuretic peptide receptor B/guanylate cyclase B (atriuretic peptide receptor B) (NPR2)	TRCN0000000427	99.19	0.46
		TRCN0000000430	99.13	0.46
NM_000294	phosphorylase kinase, gamma 2 (testis) (PHKG2)	TRCN0000000398	97.11	0.43
		TRCN0000010056	95.68	0.41
NM_005090	phospholipase A2, group IVB (cytosolic) (PLA2G4B)	TRCN0000007115	99.98	0.47
		TRCN0000007116	99.95	0.47

NM_006240	protein phosphatase, EF-hand calcium binding domain 1 (PPEF1)	TRCN0000002547	96.20	0.50
		TRCN0000002549	93.46	0.48
		TRCN0000002550	93.93	0.44
NM_006239	protein phosphatase, EF-hand calcium binding domain 2 (PPEF2)	TRCN0000002542	93.38	0.49
		TRCN0000002544	97.69	0.52
NM_030949	protein phosphatase 1, regulatory (inhibitor) subunit 14C (PPP1R14C)	TRCN0000002658	97.30	0.51
		TRCN0000002660	96.67	0.49
NM_006741	protein phosphatase 1, regulatory (inhibitor) subunit 1A (PPP1R1A)	TRCN0000002563	92.28	0.46
		TRCN0000002564	96.51	0.49
NM_002732	protein kinase, cAMP-dependent, catalytic, gamma (PRKACG)	TRCN0000022356	99.79	0.64
		TRCN0000022357	99.96	0.64
NM_000314	phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN)	TRCN0000002747	94.52	0.77
		TRCN0000002748	97.37	0.78
		TRCN0000002749	97.20	0.79
NM_006272	S100 calcium binding protein, beta (neural) (S100B)	TRCN0000053993	99.13	0.64
		TRCN0000053995	99.52	0.63
NM_020680	SCY1-like 1 (<i>S. cerevisiae</i>) (SCYL1)	TRCN0000007122	100.00	0.47
		TRCN0000007123	94.35	0.44
		TRCN0000007124	99.32	0.47
		TRCN0000007125	98.45	0.46
NM_017988	SCY1-like 2 (<i>S. cerevisiae</i>) (SCYL2)	TRCN0000007147	98.63	0.46
		TRCN0000007149	99.87	0.47
NM_003016	splicing factor, arginine/serine-rich 2 (SFRS2)	TRCN0000000082	100.00	0.67
		TRCN0000000083	100.00	0.64
		TRCN0000000091	98.20	0.07
NM_003029	SHC (Src homology 2 domain containing) transforming protein 1 (SHC1)	TRCN0000010433	94.44	0.50
		TRCN0000010434	99.29	0.67
NM_005359	SMAD, mothers against DPP homolog 4 (<i>Drosophila</i>) (SMAD4)	TRCN0000040031	96.96	0.91
		TRCN0000040032	91.91	0.90
NM_052902	serine/threonine kinase 11 interacting protein (STK11IP)	TRCN0000037800	99.34	0.56
		TRCN0000037801	99.62	0.56
		TRCN0000037803	99.36	0.55
NM_145001	serine/threonine kinase 32A (STK32A)	TRCN0000007127	99.58	0.46
		TRCN0000007130	99.98	0.46
NM_003242	transforming growth factor, beta receptor II (70/80kDa) (TGFB2)	TRCN0000000832	98.63	0.20
		TRCN0000000833	94.84	0.18

NM_012461	TERF1 (TRF1)-interacting nuclear factor 2 (TINF2)	TRCN0000010448	95.36	0.53
		TRCN0000018348	98.61	0.55
NM_021643	tribbles homolog 2 (Drosophila) (TRIB2)	TRCN0000007144	97.46	0.45
		TRCN0000007146	99.65	0.46
NM_003852	tripartite motif-containing 24 (TRIM24)	TRCN0000021259	98.78	0.46
		TRCN0000021261	95.89	0.45
		TRCN0000021263	99.95	0.47
NM_005762	tripartite motif-containing 28 (TRIM28)	TRCN0000017999	95.38	0.44
		TRCN0000018002	99.40	0.47
XM_291786	unknown kinase (UNK)	TRCN0000021379	98.26	0.45
		TRCN0000021380	100.00	0.47